文献速递重症综合管理与镇静镇痛儿科与产科急症

新鲜红细胞与标准库存红细胞输注对危重患儿多器官功能障碍综合征的影响:一项随机临床试验

Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01
一句话结论危重患儿输注新鲜红细胞(储存≤7天)与标准库存红细胞相比,未降低新发或进展性多器官功能障碍综合征发生率。

这项国际多中心、盲法随机临床试验纳入1538例危重患儿(3天至16岁,入住ICU 7天内首次输血),随机接受新鲜红细胞(储存≤7天)或标准库存红细胞。主要分析纳入1461例,新鲜组新发或进展性多器官功能障碍综合征发生率为20.2%(147/728),标准组为18.2%(133/732),未调整绝对风险差2.0%(95%CI -2.0%至6.1%;P=0.33),无显著差异。两组脓毒症、急性呼吸窘迫综合征及ICU死亡率亦无显著差异。

要点

  • 危重患儿输注新鲜红细胞(储存≤7天)与标准库存红细胞相比,新发或进展性多器官功能障碍综合征发生率无显著差异:20.2%(147/728)vs 18.2%(133/732),绝对风险差2.0%(95%CI -2.0%至6.1%;P=0.33)。
  • 新鲜组红细胞中位储存5天(IQR 4-6天),标准组18天(IQR 12-25天),P<0.001。
  • 两组ICU死亡率无显著差异:新鲜组4.5%(33/728)vs 标准组3.5%(26/732),P=0.34。
  • 两组脓毒症发生率:新鲜组25.8%(160/619)vs 标准组25.3%(154/608);急性呼吸窘迫综合征:6.6%(41/619)vs 4.8%(29/608)。
  • 作者结论:在危重患儿中,与标准库存红细胞相比,使用新鲜红细胞未降低新发或进展性多器官功能障碍综合征(包括死亡)的发生率。

适用人群与场景

  • 3天至16岁的危重患儿,纳入条件为入住ICU 7天内实施首次红细胞输注。
  • 研究在50个三级医疗中心开展,时间为2014年2月至2018年11月。

研究设计与关键结果

  • 研究类型:国际、多中心、盲法随机临床试验(Age of Transfused Blood in Critically-Ill Children trial),共筛查15568例,排除13308例,随机1538例(新鲜组768例,标准组770例)。
  • 主要分析纳入1461例(95%),中位年龄1.8岁,47.3%为女孩;新鲜组728例,标准组733例。
  • 主要终点新发或进展性多器官功能障碍综合征(评估28天或至出院或死亡):新鲜组20.2%(147/728)vs 标准组18.2%(133/732),未调整绝对风险差2.0%(95%CI -2.0%至6.1%;P=0.33),无显著差异。
  • 次要终点:脓毒症发生率新鲜组25.8%(160/619)vs 标准组25.3%(154/608);急性呼吸窘迫综合征发生率新鲜组6.6%(41/619)vs 标准组4.8%(29/608);ICU死亡率新鲜组4.5%(33/728)vs 标准组3.5%(26/732),P=0.34。

证据类型、等级与局限

  • 证据类型:国际多中心盲法随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在危重患儿中,与标准库存红细胞相比,使用新鲜红细胞未降低新发或进展性多器官功能障碍综合征(包括死亡)的发生率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial.

OBJECTIVE: To determine if the transfusion of fresh red blood cells (stored ≤7 days) reduced new or progressive multiple organ dysfunction syndrome compared with the use of standard-issue red blood cells in critically ill children.

DESIGN, SETTING, AND PARTICIPANTS: The Age of Transfused Blood in Critically-Ill Children trial was an international, multicenter, blinded, randomized clinical trial, performed between February 2014 and November 2018 in 50 tertiary care centers. Pediatric patients between the ages of 3 days and 16 years were eligible if the first red blood cell transfusion was administered within 7 days of intensive care unit admission. A total of 15 568 patients were screened, and 13 308 were excluded.

INTERVENTIONS: Patients were randomized to receive either fresh or standard-issue red blood cells. A total of 1538 patients were randomized with 768 patients in the fresh red blood cell group and 770 in the standard-issue group.

MAIN OUTCOMES AND MEASURES: The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 days or to discharge or death.

RESULTS: Among 1538 patients who were randomized, 1461 patients (95%) were included in the primary analysis (median age, 1.8 years; 47.3% girls), in which there were 728 patients randomized to the fresh red blood cell group and 733 to the standard-issue group. The median storage duration was 5 days (interquartile range [IQR], 4-6 days) in the fresh group vs 18 days (IQR, 12-25 days) in the standard-issue group (P < .001). There were no significant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 of 728 [20.2%]) and standard-issue red blood cell groups (133 of 732 [18.2%]), with an unadjusted absolute risk difference of 2.0% (95% CI, -2.0% to 6.1%; P = .33). The prevalence of sepsis was 25.8% (160 of 619) in the fresh group and 25.3% (154 of 608) in the standard-issue group. The prevalence of acute respiratory distress syndrome was 6.6% (41 of 619) in the fresh group and 4.8% (29 of 608) in the standard-issue group. Intensive care unit mortality was 4.5% (33 of 728) in the fresh group vs 3.5 % (26 of 732) in the standard-issue group (P = .34).

CONCLUSIONS AND RELEVANCE: Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01977547.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Spinella PC, Tucci M, Fergusson DA, et al. Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial. JAMA. 2019. PMID: 31821429. doi:10.1001/jama.2019.17478

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。